La chaîne d'options affiche les données clés des options sur actions de Proto Labs à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Proto Labs..

Proto Labs (NYSE:PRLB) Stock, Chaîne d'Options

Proto Labs

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.

Proto Labs Inc

WIIM

ALSN

ASTE

ATMU

CMCO

CVGI

EPAC

FELE

GTES

GTLS

LECO

NDSN

OFLX

PCAR

PKOH

PLOW

PRLB

SHYF

SPXC

TAYD

Shares of machinery companies are trading higher. Investors may be reacting to the US presidential election and its impact on the industry.

Craig-Hallum analyst Greg Palm maintains Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with a Hold and raises the price target from $30 to $36.

News

Price Target

Analyst Ratings

Craig-Hallum Maintains Hold on Proto Labs, Raises Price Target to $36

Cantor Fitzgerald analyst Troy Jensen reiterates Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with a Overweight and maintains $40 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Proto Labs, Maintains $40 Price Target

Needham analyst James Ricchiuti reiterates Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with a Hold.

Needham Reiterates Hold on Proto Labs

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Friday.
The Dow traded up 0.67% to 42,043.38 while the NASDAQ surged 0.75% to 18,230.53. The S&amp;P 500 also rose, gaining, 0.47% to 5,732.21.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.3% on Friday.
In trading on Friday, utilities shares fell by 2.1%.
Top Headline
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell around 2% on Friday after the company reported results for the fourth quarter.
The company reported fiscal fourth-quarter revenue of $94.9 billion, beating analyst estimates of $94.56 billion. The iPhone maker reported fourth-quarter adjusted earnings of $1.64 per share, beating analyst estimates of $1.60 per share.
<h3 class="wp-block-heading">Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 53% to $5.34 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 33% to $36.42 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 33% to $23.23 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 71% to $1.51 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) were down 21% to $17.30. Myriad Genetics will hold its third quarter earnings conference call on Thursday, Nov. 7.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 37% to $1.2250. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $69.79 while gold traded down 0.1% at $2,745.60.
Silver traded down 0.7% to $32.555 on Friday, while copper rose 0.3% to $4.3520.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.09%, Germany's DAX gained 0.93% and France's CAC 40 gained 0.80%. Spain's IBEX 35 Index surged 1.46%, while London's FTSE 100 rose 0.83%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
<li>The total number of active U.S. oil rigs fell by one to 479 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Markets

Trading Ideas

AAPL

CDXC

EPIX

LXRX

MYGN

TILE

Crude Oil Moves Higher; Apple Shares Slide After Q4 Results

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday.
The Dow traded up 1.18% to 42,254.81 while the NASDAQ surged 1.31% to 18,332.35. The S&amp;P 500 also rose, gaining, 0.95% to 5,759.63.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.9% on Friday.
In trading on Friday, utilities shares fell by 1.1%.
Top Headline
Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares surged 7% on Friday after the copany posted stronger-than-expected results for the third quarter.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 55% to $5.41 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 31% to $36.54 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 33% to $23.15 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 70% to $1.58 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) were down 21% to $17.24. Myriad Genetics will hold its third quarter earnings conference call on Thursday, Nov. 7.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 36% to $1.2550. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $70.04 while gold traded up 0.2% at $2,753.70.
Silver traded down 0.1% to $32.755 on Friday, while copper rose 0.5% to $4.3635.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.25%, Germany's DAX gained 1.10% and France's CAC 40 gained 1.05%. Spain's IBEX 35 Index surged 1.42%, while London's FTSE 100 rose 1.06%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

AMZN

Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Friday.
Shares of Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) rose sharply during Friday's session as the company posted stronger-than-expected results for the <a href="https://www.benzinga.com/quote/AMZN">third quarter on Thursday</a>.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Amazon.com shares jumped 7.1% to $199.63 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Proto Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) shares jumped 31.8% to $36.10 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 30% to $22.72 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) jumped 25.3% to $1.3145 after the company amended its services agreement with Apple to launch an extended MSS network with new satellites and infrastructure.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) gained 19.7% to $19.52.</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) rose 17.3% to $378.98 after the company reported third-quarter earnings and sales that beat analyst estimates.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) gained 16.5% to $96.73 following third-quarter results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) climbed 15.8% to $218.37 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>Pediatrix Medical Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) rose 15.6% to $14.26 following better-than-expected quarterly earnings.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) gained 14.2% to $7.98. ASP Isotopes announced the pricing of public offering of common stock.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) surged 13.2% to $36.32 following better-than-expected quarterly earnings.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) gained 12% to $366.93 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) gained 11.5% to $89.49.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 9.9% to $55.56 after the company reported better-than-expected quarterly financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) rose 9.6% to $14.92.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) surged 8.2% to $133.01 after the company raised its FY2024 adjusted EPS guidance.</li>
<li>Chart Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NASDAQ">GTLS</a>) gained 8.1% to $130.46 following quarterly results.</li>
<li>Dorman Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) gained 7.9% to $123.05 following upbeat earnings.</li>
<li>Magna International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) jumped 7.8% to $42.54 following third-quarter results.</li>
<li>Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) gained 7.1% to $116.21 after the company reported better-than-expected first-quarter EPS and revenues and raised its FY2025 adjusted EPS guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Intraday Update

Movers

ADMA

ASPI

CHTR

DORM

GSAT

HALO

LBRDA

MBLY

TEAM

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 400 points on Friday.
The Dow traded up 1% to 42,182.88 while the NASDAQ surged 1.18% to 18,309.37. The S&amp;P 500 also rose, gaining, 0.98% to 5,761.25.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 3.1% on Friday.
In trading on Friday, utilities shares fell by 0.1%.
Top Headline
The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.
Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 55% to $5.38 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 33% to $36.54 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 32% to $23.04 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 70% to $1.5450 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) were down 45% to $0.0325.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 34% to $1.2790. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $70.39 while gold traded up 0.4% at $2,761.30.
Silver traded up 0.3% to $32.890 on Friday, while copper rose 0.4% to $4.3575.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1%, Germany's DAX gained 0.8% and France's CAC 40 gained 0.7%. Spain's IBEX 35 Index surged 1.2%, while London's FTSE 100 rose 0.8%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

ELAB

Dow Jumps 400 Points; US Adds 12,000 Jobs In October

Shares of Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/11/41684534/charter-communications-beats-q3-estimates-on-strong-mobile-growth-expanding-margins">third-quarter EPS and revenues.</a>
Charter Communications reported fiscal third-quarter 2024 revenue growth of 1.6% year-on-year to $13.8 billion, beating the analyst consensus estimate of $13.7 billion. EPS of $8.82 beat the analyst consensus estimate of $8.67
Charter Communications shares rose 11.1% to $364.01 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Globalstar, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) gained 41.9% to $1.49 in pre-market trading after the company announced a proposed public offering.</li>
<li>Theriva Biologics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NYSE">TOVX</a>) rose 41.1% to $2.06 in pre-market trading after the company announced it was selected as a finalist for Merck KGaA&#8217;s EMEA Advance Biotech Grant.</li>
<li>Athira Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares surged 31.1% to $0.5610 in pre-market trading.</li>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) climbed 30% to $1.43 in pre-market trading after declining 11% on Thursday.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) gained 22.5% to $231.06 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) gained 18.6% to $0.5340 in pre-market trading.</li>
<li>Proto Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) gained 18.3% to $32.43 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>comScore, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) shares rose 17.3% to $6.45 in pre-market trading.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 12.8% to $57.04 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dipped 69.2% to $1.60 in pre-market trading. ESSA Pharma terminated Phase 2 study evaluating Masofaniten combined with Enzalutamide in patients with mCRPC.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) fell 37.4% to $1.2207 in pre-market trading.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) fell 35% to $0.0383 in pre-market trading.</li>
<li>MultiMetaVerse Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMV#NASDAQ">MMV</a>) declined 24.1% to $0.3331 in pre-market trading.</li>
<li>Arbe Robotics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) declined 18.7% to $1.4800 in pre-market trading after the company announced a public offering.</li>
<li>Advent Technologies Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NYSE">ADN</a>) fell 15.8% to $1.9899 in pre-market trading after jumping around 34% on Thursday.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) fell 8.4% to $6.40 in pre-market trading after the company announced a proposed public offering.</li>
<li>BJ&#8217;s Restaurants, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) fell 6.3% to $34.75 in today's pre-market trading after the company announced worse-than-expected third-quarter EPS results.</li>
<li>nVent Electric plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) shares fell 6.1% to $70.00 in pre-market trading after the company reported third-quarter results.</li>
<li>DigitalBridge Group, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NASDAQ">DBRG</a>) declined 6% to $14.75 in pre-market trading after the company reported weaker-than-expected third-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41676524/s-p-500-records-worst-session-in-over-a-month-meta-and-microsoft-tumble-greed-index-moves-to-fear-z">S&amp;P 500 Records Worst Session In Over A Month, Meta And Microsoft Tumble: Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

ARBE

ATHA

BJRI

BURU

DBRG

Eaton Vance Massachusetts Municipal Income Trust

SCOR

TOVX

VSME

Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

Proto Labs shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 adjusted EPS guidance with its midpoint above estimates.

Guidance

General

Protolabs Expects Q4 Of 2024 Adjusted EPS Of $0.28-$0.36 Versus Consensus Of $0.29, With GAAP EPS Of $0.10-$0.18 Compared To Consensus Of $0.13

Protolabs Expects Q4 Of 2024 Revenue Of $115M-$123M Versus Consensus Of $120.01M

Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.32 by 46.87 percent. This is a 7.84 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $125.62 million which beat the analyst consensus estimate of $121.38 million by 3.49 percent. This is a 3.89 percent decrease over sales of $130.71 million the same period last year.

Earnings Beats

Proto Labs Q3 2024 Adj EPS $0.47 Beats $0.32 Estimate, Sales $125.62M Beat $121.38M Estimate

Proto Labs, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prlb#NYSE">PRLB</a>) announced that it launched Axtra3D Hybrid PhotoSynthesis technology, which expands its 3D printing capabilities. The launch of HPS complements Proto Labs&#39; strategy to meet additional customer needs and extend into production use cases.
<h2>PRLB&#39;s HPS to Complement Existing Capabilities</h2>
HPS employs a precision laser and a digital light processing system to capture images of internal and external part structures at the same time. This dual 3D printing approach helps overcome previous 3D printing limitations. Common HPS applications include production-grade components with high throughput parts. It requires high-accuracy features for testing and validation, and cosmetic prototypes with glass-like surface finishes.
HPS supports the company&#39;s existing Carbon digital light synthesis printers for 3D printing projects that demand better mechanical qualities.
<h2>Current Available HPS Materials Boost Proto Labs&#39; Potential</h2>
The two currently available HPS materials include Tough Black (Loctite Henkel 3843) and Ceramic-filled (BASF 3280).
Tough Black is an engineering-grade resin with great strength and exceptional impact resistance, whereas Ceramic-filled is a stiff substance commonly used for tooling and molding. Both materials increase the company&#39;s advanced photopolymer catalog and supplement the materials previously available for Carbon DLS.
<h2>PRLB Q2 Earnings Beat Estimates, Revenues Rise Y/Y</h2>
In the second quarter of 2024, Proto Labs reported a 3.3% year-over-year increase in revenues to $126 million. The top line met the Zacks Consensus Estimate. The company reported earnings per share of 18 cents against the loss of 1 cent posted in the second quarter of 2023. The bottom line beat the Zacks Consensus Estimate of 16 cents.
<h2>Proto Labs&#39; Share Price Performance</h2>
Proto Lab&#39;s shares have gained 0.4% in the past year against the industry&#39;s 16.6% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/8c/77208.jpg?v=172366857" />
Image Source: Zacks Investment Research
<h2>PRLB&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
PRLB currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the Industrial Products sector are Crane Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cr#NYSE">CR</a>), Flowserve Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fls#NYSE">FLS</a>) and Cintas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctas#NASDAQ">CTAS</a>). These three companies have a Zacks Rank #2 at present.
The Zacks Consensus Estimate for Crane&#39;s 2024 earnings is pegged at $5.07 per share. The consensus estimate for 2024 earnings has moved north by 6% in the past 60 days. The company has a trailing four-quarter average earnings surprise of 11.2%. CR shares have gained 75.2% in a year.
Flowserve has an average trailing four-quarter earnings surprise of 18.2%. The Zacks Consensus Estimate for FLS&#39; 2024 earnings is pinned at $2.76 per share, which indicates year-over-year growth of 31.6%. The consensus estimate for 2024 earnings has moved north by 4% in the past 60 days. The company&#39;s shares have gained 27.5% in a year.
The Zacks Consensus Estimate for Cintas&#39; 2024 earnings is pegged at $16.64 per share. The consensus estimate for 2024 earnings has moved north by 1% in the past 60 days. The company has a trailing four-quarter average earnings surprise of 4%. CTAS shares have gained 60.4% in a year.
<a href="https://www.zacks.com/stock/news/2334207/proto-labs-launches-axtra3d-hps-technology-to-boost-capabilities?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2334207">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Small Cap

Tech

CTAS

Proto Labs Launches Axtra3D HPS Technology to Boost Capabilities

In a recent SEC filing, it was revealed that Robert Bodor, President and CEO at Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>), made a noteworthy insider purchase on September 9,.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001443669/000162828024039901//Archives/edgar/data/1443669/000162828024039901/0001628280-24-039901-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that Bodor purchased 3,480 shares of Proto Labs. The total transaction amounted to $99,800. 
As of Tuesday morning, Proto Labs shares are up by 0.93%, currently priced at $28.2.
<h3>About Proto Labs</h3>
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.
<h3>Proto Labs: A Financial Overview</h3>
Revenue Growth: Proto Labs's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 2.75%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: With a high gross margin of 45.01%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Proto Labs's EPS is below the industry average. The company faced challenges with a current EPS of 0.18. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Proto Labs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 29.41 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.41, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 8.69 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001443669">Check Out The Full List Of Proto Labs's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Proto Labs President and CEO Makes $99K Stock Purchase

Axtra3D printing capabilities complement digital manufacturer's advanced photopolymer offering with highly precise and repeatable printed parts in days.
Digital manufacturing leader Protolabs expanded its 3D printing capabilities today with the launch of an <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.protolabs.com%2Fservices%2F3d-printing%2Fadvanced-photopolymers%2F&amp;esheet=54118617&amp;newsitemid=20240909892648&amp;lan=en-US&amp;anchor=advanced+photopolymers+technology&amp;index=1&amp;md5=6d53469f2c8adbd656e5c371c04611e0">advanced photopolymers technology</a>. Axtra3D Hybrid PhotoSynthesis (HPS) offers highly repeatable and finely detailed 3D printed parts at accelerated speeds. HPS uses both a precision laser and digital light processing (DLP) system to simultaneously image internal and external part structures—a dual 3D printing approach that overcomes traditional limitations.
HPS complements Protolabs' current Carbon digital light synthesis (DLS) printers for 3D printing projects that require stronger mechanical properties. Both Carbon DLS and HPS feature near-isotropic parts and smooth surface finishes, but HPS technology also offers exceptionally high resolution when compared to other 3D printing processes.

Protolabs Expands 3D Printing Options with Hybrid PhotoSynthesis Technology; Axtra3D Hybrid Photosynthesis Offers Highly Repeatable And Finely Detailed 3D Printed Parts At Accelerated Speeds

Proto Labs shares are trading lower after the company reported mixed Q2 financial results and issued Q3 guidance below estimates.

Third Quarter&nbsp;2024&nbsp;Outlook
For the&nbsp;third quarter&nbsp;of 2024, the Company expects to generate revenue between&nbsp;$117 million&nbsp;and&nbsp;$125 million.
The Company expects&nbsp;third quarter&nbsp;2024 diluted net income per share between&nbsp;$0.10&nbsp;and&nbsp;$0.18, and non-GAAP diluted net income per share between&nbsp;$0.29&nbsp;and&nbsp;$0.37. See &quot;Non-GAAP Financial Measures&quot; below.

Protolabs Expects Q3 Revenue Of $117M-$125M Vs. $129.624M Consensus; Sees Adj. EPS Of $0.29-$0.37 Vs. $0.41 Consensus

Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.35 by 8.57 percent. This is a 15.15 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $125.631 million which missed the analyst consensus estimate of $126.245 million by 0.49 percent. This is a 2.75 percent increase over sales of $122.265 million the same period last year.

Earnings Misses

Proto Labs Q2 2024 Adj. EPS $0.38 Beats $0.35 Estimate, Sales $125.631M Miss $126.245M Estimate

Sees Q4 revenue $115M-$123M, consensus $120.01M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...

Protolabs sees Q4 non-GAAP EPS 28c-36c, consensus 29c

Reports Q3 revenue $125.6M, consensus $121.38M. "Our disciplined approach and resilient business model drove solid financial results in Q3, despite...

Protolabs reports Q3 non-GAAP EPS 47c, consensus 32c

Protolabs (PRLB) is up 19.9%, or $5.44 to $32.84. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Protolabs rises 19.9%

Protolabs (PRLB) is up 35.0%, or $9.59 to $36.99. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Protolabs rises 35.0%

Proto Labs, Inc. (PRLB) Q3 2024 Earnings Call Transcript

Protolabs (PRLB) is up 30.3%, or $8.30 to $35.70. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Protolabs rises 30.3%

Needham analyst James Ricchiuti has maintained their neutral stance on PRLB stock, giving a Hold rating today. James Ricchiuti has given his Hold r...

Proto Labs: Balancing Strong EPS with Future Growth Challenges – Analyst Holds Rating

Proto Labs: Solid Cash Flows But Upside Is Limited

Craig-Hallum analyst Greg Palm maintained a Hold rating on Proto Labs (PRLB – Research Report) today. The company's shares closed yesterday at $44....

Proto Labs (PRLB) Gets a Hold from Craig-Hallum

Global digital manufacturing leader Protolabs (PRLB) has expanded its capabilities with the introduction of full-service production to help serve c...

Protolabs broadens abilities from custom prototyping to full-service poduction

Legal

Press Releases

Proto Labs, Inc. (PRLB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Protolabs to Attend the Gateway Conference on September 4th

Protolabs Expands 3D Printing Options with Hybrid PhotoSynthesis Technology

Harley-Davidson® Factory Racing Elevates Podium Finishes with Protolabs

Protolabs Sets Conference Call to Discuss Third Quarter 2024 Financial Results

Protolabs Reports Financial Results for the Third Quarter of 2024

Protolabs Expands End-to-End Manufacturing Capabilities from Custom Prototyping to Full-Service Production

Comments

Proto Labs

Proto Labs (PRLB) Options

Proto Labs (NYSE:PRLB) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL